Daily Editorial Analysis for 27th November 2020

  1. Home
  2. »
  3. Editorial Analysis November 2020
  4. »
  5. Daily Editorial Analysis for 27th November 2020

Rein in the vaccine nationalism, the profiteering


Mains: G.S. II, III & IV Social Justice, Science and Tech, Economy related issues and Ethics, Integrity and Aptitude


  • It is illegal to hoard, for black marketing, essential goods in drought-affected areas.
  • Overcharging of commodities and services during any natural disaster is always a scandal.
  • It is a crime against humanity to make a profit during any human tragedy.
  • There should be empathy and concern about human suffering.
  • Such solidarity is a recognition of the need to: prevent further damage and destruction, rescue and evacuate affected people to safer zones, and salvage belongings and meet their minimal survival needs.
  • For this nobody is charged. Instead, it is considered as relief work which comes out profusely as charity; a humane gesture.


  • The COVID-19 pandemic is also a human tragedy and needs global solidarity. It is definitely not a time to be doing business and making a fast buck.
  • Making enormous profit out of a human tragedy is shameful.
  • Unfortunately, such a sense of shame is missing in the international trade market.
  • When economies crumbled in many countries, e-commerce and gadget-based gaming business boomed. And in the novel coronavirus pandemic, there are numerous examples of companies having made enormous profits in the supply of personal protective equipment and kits and ventilators.
  • In a liberalised economy, there is a shocking silence in the global market trying to do business out of human suffering.
  • Business lies in selling technologies, around COVID-19, the diagnostics, drugs and vaccine candidates.
  • This is where organisations of the United Nations and global networks for people should come together in one voice.
  • When the entire global population, estimated to be nearly eight billion people, is in need of a vaccine (still being tested and yet to be approved) then production at full capacity and supply to every country will take time.
  • We cannot allow the rich and the strong to grab everything first. The advance purchase agreements that some countries have negotiated with pharmaceutical companies exemplify such adverse trends.
  • There has to be prioritisation for high-risk groups in all countries, especially in the least developed, low- and middle-income nations.
  • That framework has to be accepted by the global community without dispute. In this, the COVAX partnership is a mechanism for ensuring that.
  • GAVI, or the Global Alliance for Vaccine Initiative, was in existence during the pre-COVID-19 period to ensure the pooled procurement and equitable supply of life-saving vaccines to low-and middle-income countries. It has been roped in for the COVID-19 vaccine too.
  • Tedros Adhanom Ghebreyesus, the World Health Organization Director General, on June 13, exhorted member countries to treat COVID-19 technologies as a “public good”. Obviously it fell on deaf ears as far as pharmaceutical companies were concerned.
  • A public good is a common property of the nation and such goods are not excludable or there should not be any rivalries in dealing with it. If it is a public good, governments must step in to regulate its development, innovation, manufacture, sale, and supply ultimately to the public. If there is public financing for technology development, there is no scope for grant of patent protection.
  • A public good cannot be submitted to the vagaries of market fluctuations of pricing dependent on demand-supply dynamics. Governments should be the custodian of public goods.
  • If such an idealistic outcome does not materialise based on basic human rights for availability of accessible and affordable health care, then some regulation mandated by the UN General Assembly must be thought of.
  • The World Trade Organisation (WTO) had raised concern over public health with regard to the non-availability of patented drugs in sufficient quantity, and at affordable prices.
  • Seizing the opportunity of the WTO itself mapping out key trade issues arising out of COVID-19 vaccine and fostering dialogue, India and South Africa jointly sent out a communication, on October 2, 2020 to the IPR Council of the WTO for a waiver of the protection of copyright, design, trademarks and patent on COVID-19 related technologies including vaccines.


  • A UN organisation such as the WTO can wield influence on member-nations to forgo trade profits for a humanitarian cause.
  • Global campaigns through the media and civil society organisations can garner enough momentum to exert pressure on TRIPS. This is a pragmatic step for the time being.
  • But having nothing less than vaccines and life-saving medicines being treated as a public good must definitely be the long-term goal.

Current Affairs

Recent Posts